Hunan Warrant Pharmaceutical Co. Ltd. A (688799) - Total Assets

Latest as of June 2025: CN¥2.53 Billion CNY ≈ $369.58 Million USD

Based on the latest financial reports, Hunan Warrant Pharmaceutical Co. Ltd. A (688799) holds total assets worth CN¥2.53 Billion CNY (≈ $369.58 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688799 net assets for net asset value and shareholders' equity analysis.

Hunan Warrant Pharmaceutical Co. Ltd. A - Total Assets Trend (2019–2024)

This chart illustrates how Hunan Warrant Pharmaceutical Co. Ltd. A's total assets have evolved over time, based on quarterly financial data.

Hunan Warrant Pharmaceutical Co. Ltd. A - Asset Composition Analysis

Current Asset Composition (December 2024)

Hunan Warrant Pharmaceutical Co. Ltd. A's total assets of CN¥2.53 Billion consist of 58.3% current assets and 41.7% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 7.2%
Accounts Receivable CN¥168.31 Million 6.8%
Inventory CN¥412.43 Million 16.8%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥186.09 Million 7.6%
Goodwill CN¥32.38 Million 1.3%

Asset Composition Trend (2019–2024)

This chart illustrates how Hunan Warrant Pharmaceutical Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hunan Warrant Pharmaceutical Co. Ltd. A market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Hunan Warrant Pharmaceutical Co. Ltd. A's current assets represent 58.3% of total assets in 2024, an increase from 46.5% in 2019.
  • Cash Position: Cash and equivalents constituted 7.2% of total assets in 2024, down from 8.3% in 2019.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 4.0% in 2019.
  • Asset Diversification: The largest asset category is inventory at 16.8% of total assets.

Hunan Warrant Pharmaceutical Co. Ltd. A Competitors by Total Assets

Key competitors of Hunan Warrant Pharmaceutical Co. Ltd. A based on total assets are shown below.

Company Country Total Assets
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
China CN¥21.15 Billion
Emcure Pharmaceuticals Ltd
NSE:EMCURE
India Rs93.93 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Ningbo Menovo Pharm Co Ltd
SHG:603538
China CN¥4.75 Billion
GALDERMA GROUP AG
NYSE:GALDY
USA $13.39 Billion
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Sweden Skr67.43 Billion
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
China CN¥3.02 Billion

Hunan Warrant Pharmaceutical Co. Ltd. A - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.03 4.25 4.39
Quick Ratio 2.79 3.07 3.22
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥1.02 Billion CN¥1.10 Billion CN¥943.67 Million

Hunan Warrant Pharmaceutical Co. Ltd. A - Advanced Valuation Insights

This section examines the relationship between Hunan Warrant Pharmaceutical Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.22
Latest Market Cap to Assets Ratio 0.44
Asset Growth Rate (YoY) 13.0%
Total Assets CN¥2.46 Billion
Market Capitalization $1.09 Billion USD

Valuation Analysis

Below Book Valuation: The market values Hunan Warrant Pharmaceutical Co. Ltd. A's assets below their book value (0.44x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Hunan Warrant Pharmaceutical Co. Ltd. A's assets grew by 13.0% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Hunan Warrant Pharmaceutical Co. Ltd. A (2019–2024)

The table below shows the annual total assets of Hunan Warrant Pharmaceutical Co. Ltd. A from 2019 to 2024.

Year Total Assets Change
2024-12-31 CN¥2.46 Billion
≈ $359.92 Million
+12.99%
2023-12-31 CN¥2.18 Billion
≈ $318.56 Million
+8.36%
2022-12-31 CN¥2.01 Billion
≈ $293.98 Million
+11.76%
2021-12-31 CN¥1.80 Billion
≈ $263.04 Million
+95.15%
2020-12-31 CN¥921.12 Million
≈ $134.79 Million
+8.18%
2019-12-31 CN¥851.44 Million
≈ $124.59 Million
--

About Hunan Warrant Pharmaceutical Co. Ltd. A

SHG:688799 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.09 Billion
CN¥7.47 Billion CNY
Market Cap Rank
#8767 Global
#2317 in China
Share Price
CN¥56.86
Change (1 day)
-3.10%
52-Week Range
CN¥41.05 - CN¥65.58
All Time High
CN¥65.58
About

Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products. It offers medicines in the areas of digestive, berating, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology and nephrology, and other fields. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha, China.